Since its inception, the MRFBC has grown to include 16 participating academic centers, including all five of the NCI-supported Specialized Programs of Research Excellence (SPORES) in melanoma:
“When operating as individual institutions, even the largest melanoma programs are limited by the inability to rapidly address questions of immediate importance. When there is consensus that a new hypothesis needs to be tested in a clinical trial, we cannot wait years for results that can be generated in months through collaboration.”
- Keith Flaherty, M.D., Director of Developmental Therapeutics, Massachusetts General Hospital
Learn about the MRFBC's Mission and Core Strategies.